Regeneron Pharmaceuticals
Utility Patents

Last updated:

List of all Regeneron Pharmaceuticals patents 248 in total

Status Patent
Grant
Utility: Genetically modified rodent with an inducible ACVR1 mutation in exon 7 that causes ectopic bone formation External link
Filling date: 12 Sep 2025 Issue date: 23 Aug 2022
Grant
Utility: Bispecific anti-CD28 .times. anti-CD22 antibodies and uses thereof External link
Filling date: 12 Sep 2025 Issue date: 26 Jul 2022
Grant
Utility: Metabolically optimized cell culture External link
Filling date: 12 Sep 2025 Issue date: 19 Jul 2022
Grant
Utility: Bispecific anti-BCMA x anti-CD3 antibodies and uses thereof External link
Filling date: 12 Sep 2025 Issue date: 12 Jul 2022
Grant
Utility: Anti-MSR1 antibodies and methods of use thereof External link
Filling date: 12 Sep 2025 Issue date: 5 Jul 2022
Grant
Utility: Methods for evaluating suitability of a biochemical filter External link
Filling date: 12 Sep 2025 Issue date: 5 Jul 2022
Grant
Utility: Taurine supplemented cell culture medium and methods of use External link
Filling date: 12 Sep 2025 Issue date: 26 Apr 2022
Grant
Utility: Anti-VEGF protein compositions and methods for producing the same External link
Filling date: 12 Sep 2025 Issue date: 19 Apr 2022
Grant
Utility: Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody External link
Filling date: 12 Sep 2025 Issue date: 19 Apr 2022
Grant
Utility: Anti-NPR1 antibodies and uses thereof External link
Filling date: 12 Sep 2025 Issue date: 19 Apr 2022
Grant
Utility: Anti-VEGF protein compositions and methods for producing the same External link
Filling date: 12 Sep 2025 Issue date: 12 Apr 2022
Grant
Utility: Anti-PD-1 antibodies for treatment of lung cancer External link
Filling date: 12 Sep 2025 Issue date: 5 Apr 2022
Grant
Utility: Human serum albumin in formulations External link
Filling date: 12 Sep 2025 Issue date: 8 Feb 2022
Grant
Utility: Mice that make heavy chain antibodies External link
Filling date: 12 Sep 2025 Issue date: 1 Feb 2022
Grant
Utility: Genetically modified major histocompatibility complex mice External link
Filling date: 12 Sep 2025 Issue date: 18 Jan 2022
Grant
Utility: Non-human animals expressing pH-sensitive immunoglobulin sequences External link
Filling date: 12 Sep 2025 Issue date: 18 Jan 2022
Grant
Utility: Genetically modified major histocompatibility complex mice External link
Filling date: 12 Sep 2025 Issue date: 11 Jan 2022
Grant
Utility: Compositions and methods for internalizing enzymes External link
Filling date: 12 Sep 2025 Issue date: 28 Dec 2021
Grant
Utility: Histidine engineered light chain antibodies and genetically modified non-human animals for generating same External link
Filling date: 12 Sep 2025 Issue date: 7 Dec 2021
Grant
Utility: Multispecific antigen-binding molecules and uses thereof External link
Filling date: 12 Sep 2025 Issue date: 7 Dec 2021
Grant
Utility: Non-human animals expressing humanized C1Q complex External link
Filling date: 12 Sep 2025 Issue date: 30 Nov 2021
Grant
Utility: Humanized C5 animals External link
Filling date: 12 Sep 2025 Issue date: 23 Nov 2021
Grant
Utility: Anti-VEGF protein compositions and methods for producing the same External link
Filling date: 12 Sep 2025 Issue date: 16 Nov 2021
Grant
Utility: Human antibodies to Fel d1 and methods of use thereof External link
Filling date: 12 Sep 2025 Issue date: 16 Nov 2021
Grant
Utility: Readily isolated bispecific antibodies with native immunoglobulin format External link
Filling date: 12 Sep 2025 Issue date: 9 Nov 2021
Grant
Utility: Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof External link
Filling date: 12 Sep 2025 Issue date: 26 Oct 2021
Grant
Utility: Cas-ready mouse embryonic stem cells and mice and uses thereof External link
Filling date: 12 Sep 2025 Issue date: 28 Sep 2021
Grant
Utility: Anti-Zika virus antibodies and methods of use External link
Filling date: 12 Sep 2025 Issue date: 14 Sep 2021
Grant
Utility: Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) External link
Filling date: 12 Sep 2025 Issue date: 14 Sep 2021
Grant
Utility: Humanized IL-4 and IL-4Ra animals External link
Filling date: 12 Sep 2025 Issue date: 7 Sep 2021
Grant
Utility: Non-human animals that select for light chain variable regions that bind antigen External link
Filling date: 12 Sep 2025 Issue date: 7 Sep 2021
Grant
Utility: Methods for producing aflibercept in chemically defined media having reduced aflibercept variants External link
Filling date: 12 Sep 2025 Issue date: 31 Aug 2021
Grant
Utility: Humanized IL-6 and IL-6 receptor External link
Filling date: 12 Sep 2025 Issue date: 31 Aug 2021
Grant
Utility: High concentration VEGF receptor fusion protein containing formulations External link
Filling date: 12 Sep 2025 Issue date: 31 Aug 2021
Grant
Utility: Non-human animals having a humanized lymphocyte-activation gene 3 External link
Filling date: 12 Sep 2025 Issue date: 31 Aug 2021
Grant
Utility: Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors External link
Filling date: 12 Sep 2025 Issue date: 31 Aug 2021
Grant
Utility: Anti-VEGF protein compositions and methods for producing the same External link
Filling date: 12 Sep 2025 Issue date: 24 Aug 2021
Grant
Utility: Anti-VEGF protein compositions and methods for producing the same External link
Filling date: 12 Sep 2025 Issue date: 24 Aug 2021
Grant
Utility: Cornulin (CRNN) variants and uses thereof External link
Filling date: 12 Sep 2025 Issue date: 24 Aug 2021
Grant
Utility: Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies External link
Filling date: 12 Sep 2025 Issue date: 24 Aug 2021
Grant
Utility: VEGF antagonist formulations suitable for intravitreal administration External link
Filling date: 12 Sep 2025 Issue date: 10 Aug 2021
Grant
Utility: Efficient selectivity of recombinant proteins External link
Filling date: 12 Sep 2025 Issue date: 10 Aug 2021
Grant
Utility: Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab External link
Filling date: 12 Sep 2025 Issue date: 27 Jul 2021
Grant
Utility: Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof External link
Filling date: 12 Sep 2025 Issue date: 27 Jul 2021
Grant
Utility: VEGF antagonist formulations suitable for intravitreal administration External link
Filling date: 12 Sep 2025 Issue date: 20 Jul 2021
Grant
Utility: Production cell line enhancers External link
Filling date: 12 Sep 2025 Issue date: 20 Jul 2021
Grant
Utility: Anti-TrkB monoclonal antibodies and methods of use External link
Filling date: 12 Sep 2025 Issue date: 20 Jul 2021
Grant
Utility: Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies External link
Filling date: 12 Sep 2025 Issue date: 13 Jul 2021
Grant
Utility: Anti-VEGF protein compositions and methods for producing the same External link
Filling date: 12 Sep 2025 Issue date: 6 Jul 2021
Grant
Utility: Genetically modified mice and engraftment External link
Filling date: 12 Sep 2025 Issue date: 6 Jul 2021

Showing 1 to 50 of 248 patents.